Chilton Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.42M | Buy |
13,608
+213
| +2% | +$45.8K | 0.11% | 86 |
|
|
2026
Q1 | $2.91M | Sell |
13,395
-50
| -0.4% | -$11.1K | 0.1% | 92 |
|
|
2025
Q4 | $3.07M | Sell |
13,445
-39
| -0.3% | -$8.88K | 0.11% | 91 |
|
|
2025
Q3 | $3.12M | Buy |
13,484
+282
| +2% | +$57.4K | 0.1% | 92 |
|
|
2025
Q2 | $2.45M | Buy |
13,202
+39
| +0.3% | +$7.25K | 0.09% | 93 |
|
|
2025
Q1 | $2.76M | Sell |
13,163
-244
| -2% | -$47.4K | 0.12% | 91 |
|
|
2024
Q4 | $2.38M | Sell |
13,407
-74
| -0.5% | -$13.6K | 0.1% | 93 |
|
|
2024
Q3 | $2.66M | Sell |
13,481
-223
| -2% | -$41.6K | 0.11% | 93 |
|
|
2024
Q2 | $2.35M | Buy |
13,704
+240
| +2% | +$39.8K | 0.11% | 96 |
|
|
2024
Q1 | $2.45M | Sell |
13,464
-1,212
| -8% | -$209K | 0.12% | 96 |
|
|
2023
Q4 | $2.27M | Buy |
14,676
+73
| +0.5% | +$10.6K | 0.12% | 98 |
|
|
2023
Q3 | $2.18M | Sell |
14,603
-480
| -3% | -$70.5K | 0.12% | 94 |
|
|
2023
Q2 | $2.03M | Buy |
15,083
+410
| +3% | +$60.1K | 0.11% | 94 |
|
|
2023
Q1 | $2.34M | Sell |
14,673
-10
| -0.1% | -$1.53K | 0.13% | 92 |
|
|
2022
Q4 | $2.37M | Sell |
14,683
-244
| -2% | -$37.4K | 0.15% | 91 |
|
|
2022
Q3 | $2M | Sell |
14,927
-171
| -1% | -$24.5K | 0.13% | 92 |
|
|
2022
Q2 | $2.31M | Sell |
15,098
-1,679
| -10% | -$257K | 0.14% | 94 |
|
|
2022
Q1 | $2.72M | Sell |
16,777
-3
| -0% | -$436 | 0.14% | 93 |
|
|
2021
Q4 | $2.27M | Sell |
16,780
-5
| -0% | -$591 | 0.12% | 99 |
|
|
2021
Q3 | $1.81M | Sell |
16,785
-50
| -0.3% | -$5.71K | 0.1% | 105 |
|
|
2021
Q2 | $1.9M | Buy |
16,835
+413
| +3% | +$46.5K | 0.11% | 105 |
|
|
2021
Q1 | $1.78M | Sell |
16,422
-8
| -0% | -$856 | 0.12% | 101 |
|
|
2020
Q4 | $1.76M | Sell |
16,430
-57
| -0.3% | -$5.48K | 0.13% | 92 |
|
|
2020
Q3 | $1.44M | Buy |
16,487
+12,000
| +267% | +$1.13M | 0.11% | 97 |
|
|
2020
Q2 | $441K | Sell |
4,487
-149
| -3% | -$13.1K | 0.04% | 141 |
|
|
2020
Q1 | $353K | Sell |
4,636
-475
| -9% | -$40.5K | 0.04% | 145 |
|
|
2019
Q4 | $453K | Sell |
5,111
-275
| -5% | -$22.8K | 0.04% | 156 |
|
|
2019
Q3 | $408K | Sell |
5,386
-300
| -5% | -$20.6K | 0.03% | 161 |
|
|
2019
Q2 | $413K | Buy |
5,686
+450
| +9% | +$35.4K | 0.04% | 160 |
|
|
2019
Q1 | $422K | Hold |
5,236
| – | – | 0.04% | 158 |
|
|
2018
Q4 | $483K | Sell |
5,236
-1,011
| -16% | -$88.9K | 0.05% | 154 |
|
|
2018
Q3 | $591K | Sell |
6,247
-2,460
| -28% | -$233K | 0.05% | 162 |
|
|
2018
Q2 | $807K | Buy |
8,707
+2,542
| +41% | +$248K | 0.07% | 146 |
|
|
2018
Q1 | $584K | Sell |
6,165
-3,655
| -37% | -$402K | 0.05% | 153 |
|
|
2017
Q4 | $950K | Sell |
9,820
-40
| -0.4% | -$3.77K | 0.09% | 115 |
|
|
2017
Q3 | $876K | Sell |
9,860
-1,240
| -11% | -$94.4K | 0.08% | 112 |
|
|
2017
Q2 | $805K | Sell |
11,100
-64,759
| -85% | -$4.35M | 0.09% | 109 |
|
|
2017
Q1 | $4.94M | Sell |
75,859
-1,884
| -2% | -$118K | 0.49% | 70 |
|
|
2016
Q4 | $4.87M | Buy |
77,743
+21,833
| +39% | +$1.33M | 0.51% | 69 |
|
|
2016
Q3 | $3.53M | Sell |
55,910
-19,795
| -26% | -$1.28M | 0.36% | 73 |
|
|
2016
Q2 | $4.69M | Sell |
75,705
-80,007
| -51% | -$4.88M | 0.45% | 73 |
|
|
2016
Q1 | $8.89M | Buy |
155,712
+83
| +0.1% | +$4.63K | 0.89% | 47 |
|
|
2015
Q4 | $9.22M | Sell |
155,629
-43,635
| -22% | -$2.51M | 0.97% | 41 |
|
|
2015
Q3 | $10.8M | Buy |
199,264
+16,794
| +9% | +$1.09M | 1.12% | 35 |
|
|
2015
Q2 | $12.3M | Sell |
182,470
-19,819
| -10% | -$1.29M | 1.15% | 30 |
|
|
2015
Q1 | $11.8M | Buy |
202,289
+30,332
| +18% | +$1.83M | 1.19% | 27 |
|
|
2014
Q4 | $11.3M | Buy |
+171,957
| New | +$10.8M | 1.14% | 30 |
|
|
2014
Q1 | – | Sell |
-1,098
| Closed | -$58K | – | 161 |
|
|
2013
Q4 | $58K | Hold |
1,098
| – | – | 0.01% | 247 |
|
|
2013
Q3 | $49.1K | Sell |
1,098
-408
| -27% | -$18.1K | 0.01% | 255 |
|
|
2013
Q2 | $62K | Buy |
+1,506
| New | +$65.9K | 0.01% | 249 |
|
Other funds holding ABBV
Chilton Capital Management's ABBV Position: Q2 2026 in Review
Chilton Capital Management increased its AbbVie (ABBV) stake by 1.6% in Q2 2026, buying an estimated $45.8K and bringing the position to 13,608 shares worth $3.42M. The position accounts for 0.11% of the portfolio, ranked #86.
Chilton Capital Management first reported a position in ABBV in Q2 2013 and has held it in 50 quarters since. The position peaked at $12.3M in Q2 2015. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Chilton Capital Management held 13,608 shares of AbbVie worth $3.42M as of Q2 2026.
- Chilton Capital Management bought 213 AbbVie shares in Q2 2026, an estimated $45.8K.
- AbbVie made up 0.11% of Chilton Capital Management's portfolio in Q2 2026, its #86 holding.
- Chilton Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 50 quarters since.
- Chilton Capital Management's AbbVie position peaked at $12.3M in Q2 2015.
- 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Chilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.